Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | March 03, 2026 | March 05, 2026 |
| VEEVA SYSTEMS INCVEEV · Entity 2124 | Director | June 01, 2025 | June 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,140.944 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Sale · Disposed 1,758 · Balance 18,140.944 F1: Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | Indirectjointly with spouse | 160 |
Reported balance
Holding disclosure · report date 2026-03-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 160 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
VEEVA SYSTEMS INC
Report date June 01, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,202 |
Reported balance
After 2025-06-01 transaction · row 1
1 source rowRow 1 · 2025-06-01 · Exercise / conversion · Acquired 343 · Balance 4,202 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-01 · Exercise / conversion · Disposed 343 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
F3: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2021 Filed Feb 18, 2021 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 88 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 199 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004323 · doc1.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 22:07 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,098 | $470.08 | $986,228.05 |
DisclosureSEC source: 0001567619-20-018873 · doc1.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,571 F1 · balance_after: Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,107 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · derivative · entry 7 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769 Underlying: Common Stock · 1,107 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 1,906 shares of Issuer common stock that vests as to 1 share on February 14, 2017, 29 shares on February 14, 2018, 365 shares on February 14, 2019, 742 shares on February 14, 2020 and as to the remainder on February 14, 2021. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 698 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · derivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 698 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 1,366 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,107 | $67.85 | $75,109.95 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 698 | $79.54 | $55,518.92 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $377.51 | $37,751.00 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,847 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,676 | $377.50 | $1,010,190.00 |
DisclosureSEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,947 F1 · balance_after: Includes a total of 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 14 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,953 Underlying: Common Stock · 127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 13 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,080 Underlying: Common Stock · 126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F8 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 88 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 12 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,206 Underlying: Common Stock · 88 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F8 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 199 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 11 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294 Underlying: Common Stock · 199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F8 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 10 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,493 Underlying: Common Stock · 157 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F8 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650 Underlying: Common Stock · 693 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F8 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 7,125 | Not disclosed Strike: $288.78 | Not disclosed |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires 2030-02-13 F8 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2021. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 217 | $288.78 | $62,665.26 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,585 Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 127 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 88 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 199 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 157 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004363 · doc1.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.